Tube Versus Trabeculectomy IRIS&#xAE; Registry One-Year Composite Outcome Analysis with Comparisons to the Randomized Controlled Trial: (60 characters or fewer): Tube vs Trab IRIS Registry 1-Year Composite Outcome Analysis

Further Publications

The Tube Versus Trabeculectomy IRIS® Registry Study: Cohort Selection and Follow-up and Comparisons to the Randomized Controlled Trial

Am J Ophthalmol

Vanner EA, Sun CQ, McSoley MJ, Persad PJ, Feuer WJ, Lum F, Kelly S, Parrish RK, Chang TC, Gedde SJ

doi: 10.1016/j.ajo.2020.11.014

Glaucoma and Ocular Pressure

Treatment Outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study after 3 Years of Follow-up

Ophthalmology.

Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed II, Brandt JD, Primary Tube Versus Trabeculectomy Study Group.

doi: 10.1016/j.ophtha.2019.10.002.

Blindness and Vision Impairment

A Randomized Clinical Trial Of Immediate versus Delayed Spectacles for Moderate Hyperopia in 1- and 2-Year-Olds

Ophthalmology.

Kulp MT, Holmes JM, Dean TW, Suh DW, Kraker RT, Wallace DK, Petersen DB, Cotter SA, Manny RE, Superstein R, Roberts TL, Avallone JM, Fishman DR, Erzurum SA, Leske D2, Christoff A; Pediatric Eye Disease Investigator Group

doi: 10.1016/j.ophtha.

COMMENTED

Macular Diseases

Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study

Ophthalmology.

Kertes PJ, Galic IJ, Greve M, Williams RG, Rampakakis E, Scarino A, Sheidow T

doi: 10.1016/j.ophtha.

COMMENTED

Retinal Diseases

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

JAMA Ophthalmol.

Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL 3rd, Gardner TW, Jampol LM, Martin DF, Melia M, Stockdale CR, Beck RW, Diabetic Retinopathy Clinical Research Network

doi: 10.1001/jamaophthalmol.

Retinal DiseasesSurgery and Intervention

Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial

JAMA Ophthalmol

Glassman AR, Beaulieu WT, Maguire MG, Antoszyk AN, Chow CC, Elman MJ, Jampol LM, Salehi-Had H, Sun JK, DRCR Retina Network.

doi: 10.1001/jamaophthalmol.2021.1110

COMMENTED

Macular Diseases

Randomized Trial of Treat & Extend Ranibizumab With & Without Navigated Laser versus Monthly Dosing for DME: TREX-DME 2 Year Outcomes

Am J Ophthalmol.

Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group

doi: 10.1016/j.ajo.

COMMENTED

Ocular Oncology

Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals

★ 3 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

doi: 10.1001/jamaophthalmol.2019.5132.

RECOMMENDED

Macular Diseases

Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry

★ 3 Recommended by Prof. Dr Daniel Barthelmes, Faculty Member

★ 3 Recommended by Prof. Dr Ke Yao, Faculty Member

Ophthalmology.

Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle PH, Creuzot-Garcher C, Gillies M, Barthelmes D

doi: 10.1016/j.ophtha.2019.11.018.

Related content

The Tube Versus Trabeculectomy IRIS® Registry Study: Cohort Selection and Follow-up and Comparisons to the Randomized Controlled Trial

Treatment Outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study after 3 Years of Follow-up

A Randomized Clinical Trial Of Immediate versus Delayed Spectacles for Moderate Hyperopia in 1- and 2-Year-Olds

Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial

Randomized Trial of Treat & Extend Ranibizumab With & Without Navigated Laser versus Monthly Dosing for DME: TREX-DME 2 Year Outcomes

Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals

Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry